Cellectis S.A.
CLLS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001627281
No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Cellectis S.A. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 51 | 45 | −6 |
| Shares | 12.3M | 10.8M | −1.44M (−11.7%) |
| Value | $55.8M | $30.6M | −$25.1M (−45.1%) |
New holders (5)
Institutions that held Cellectis S.A. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 23,589 | $67.0K | 0.00% |
| Virtu Financial LLC | 16,366 | $46.0K | 0.00% |
| National Bank of Canada | 3,600 | $10.0K | 0.00% |
| BNP Paribas Arbitrage, SA | 229 | $648 | 0.00% |
| Toronto Dominion Bank | 31 | $0 | 0.00% |
Sold out (11)
Institutions that held Cellectis S.A. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Two Sigma Investments, LP | 131,848 | $599.0K |
| Goldman Sachs Group Inc | 53,223 | $242.0K |
| Trexquant Investment LP | 38,455 | $175.0K |
| Mitsubishi UFJ Kokusai Asset Management Co., Ltd. | 33,595 | $153.0K |
| Vident Investment Advisory, LLC | 17,696 | $80.0K |
| Old Mission Capital LLC | 17,068 | $77.0K |
| Aquatic Capital Management LLC | 2,500 | $11.0K |
| Quadrant Capital Group LLC | 1,036 | $5.00K |
| Money Concepts Capital Corp | 515 | $2.00K |
| TCWP LLC | 325 | $1.00K |
| Koshinski Asset Management, Inc. | 200 | $908 |